TWI339578B - Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions - Google Patents

Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions

Info

Publication number
TWI339578B
TWI339578B TW094134920A TW94134920A TWI339578B TW I339578 B TWI339578 B TW I339578B TW 094134920 A TW094134920 A TW 094134920A TW 94134920 A TW94134920 A TW 94134920A TW I339578 B TWI339578 B TW I339578B
Authority
TW
Taiwan
Prior art keywords
group
medicament
preparation
treatment
pyridine compound
Prior art date
Application number
TW094134920A
Other languages
English (en)
Other versions
TW200621246A (en
Inventor
Tamotsu Takagi
Atsuko Naotsuka
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of TW200621246A publication Critical patent/TW200621246A/zh
Application granted granted Critical
Publication of TWI339578B publication Critical patent/TWI339578B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW094134920A 2004-10-29 2005-10-06 Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions TWI339578B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004315553 2004-10-29

Publications (2)

Publication Number Publication Date
TW200621246A TW200621246A (en) 2006-07-01
TWI339578B true TWI339578B (en) 2011-04-01

Family

ID=36227994

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094134920A TWI339578B (en) 2004-10-29 2005-10-06 Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions

Country Status (11)

Country Link
US (1) US8809360B2 (zh)
EP (1) EP1804797B1 (zh)
KR (1) KR100982920B1 (zh)
CN (1) CN101052400B (zh)
AT (1) ATE554767T1 (zh)
AU (1) AU2005297795B2 (zh)
CA (1) CA2583492C (zh)
ES (1) ES2383531T3 (zh)
MX (1) MX2007005175A (zh)
TW (1) TWI339578B (zh)
WO (1) WO2006046774A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868019B2 (en) * 2005-10-05 2011-01-11 Mitsubishi Tanabe Pharma Corporation Dermatitis treating agent
US9555025B2 (en) * 2011-03-31 2017-01-31 Maruho Co., Ltd. Ointment with excellent formulation stability
ES2659458T3 (es) * 2011-06-28 2018-03-15 Mitsubishi Tanabe Pharma Corporation Compuestos de naftaleno para tratar el prurito
EP2868659B1 (en) 2011-08-25 2016-05-04 Mitsubishi Tanabe Pharma Corporation Method for producing optically active naphthalene compound
WO2014107663A2 (en) * 2013-01-07 2014-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
EP3603653B1 (en) 2017-03-21 2023-08-23 Well Stone Co. Production method of therapeutic agent for skin lesions, and its use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2233041A (en) 1989-06-17 1991-01-02 Fleming Thermodynamics Ltd Screw expander/compressor
JP3042156B2 (ja) 1992-02-20 2000-05-15 田辺製薬株式会社 ナフタレン誘導体、その製法及びその合成中間体
US6514996B2 (en) 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
JPH10147585A (ja) * 1996-11-19 1998-06-02 Kyowa Hakko Kogyo Co Ltd 含酸素複素環化合物
IL118469A (en) 1995-06-15 2000-08-13 Tanabe Seiyaku Co Naphthalene derivatives their preparation and intermediates thereof
JP3033090B2 (ja) * 1995-06-15 2000-04-17 田辺製薬株式会社 ナフタレン誘導体、その製法及びその合成中間体
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
JP3951395B2 (ja) * 1996-12-13 2007-08-01 田辺製薬株式会社 ピリジン誘導体、その製法及びその合成中間体
US6127363A (en) * 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
GB2333041A (en) 1998-01-13 1999-07-14 Johnson & Johnson Medical Ltd Wound Composition
JP2001031679A (ja) * 1998-08-26 2001-02-06 Tanabe Seiyaku Co Ltd ナフチリジン誘導体及びその製法
US20020065286A1 (en) 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
GB0020588D0 (en) 2000-08-21 2000-10-11 Pfizer Ltd Treatment of wounds
CA2447618A1 (en) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. A composition for regenerative treatment of cartilage disease
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
AU2003245711A1 (en) 2002-02-11 2003-09-04 Pfizer Inc. Nicotinamide derivatives useful as pde4 inhibitors
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
SE0200667D0 (sv) 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
US20040038958A1 (en) 2002-07-11 2004-02-26 Chris Rundfeldt Topical treatment of skin diseases
AU2003286555A1 (en) 2002-10-22 2004-05-13 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
JP2004196785A (ja) 2002-12-02 2004-07-15 Kyowa Hakko Kogyo Co Ltd フロピリジン誘導体

Also Published As

Publication number Publication date
EP1804797B1 (en) 2012-04-25
ES2383531T3 (es) 2012-06-22
CA2583492C (en) 2010-11-30
ATE554767T1 (de) 2012-05-15
AU2005297795A1 (en) 2006-05-04
CN101052400A (zh) 2007-10-10
EP1804797A4 (en) 2007-12-26
CA2583492A1 (en) 2006-05-04
WO2006046774A1 (en) 2006-05-04
MX2007005175A (es) 2007-07-04
US20090069307A1 (en) 2009-03-12
KR100982920B1 (ko) 2010-09-20
CN101052400B (zh) 2010-12-29
EP1804797A1 (en) 2007-07-11
AU2005297795B2 (en) 2009-03-12
US8809360B2 (en) 2014-08-19
TW200621246A (en) 2006-07-01
KR20070074584A (ko) 2007-07-12

Similar Documents

Publication Publication Date Title
WO2006011631A3 (en) Thiazole derivatives having vap-1 inhibitory activity
DK1326613T4 (da) Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering
TWI339578B (en) Use of a pyridine compound for the preparation of a medicament for the treatment of skin lesions
WO2006078621A3 (en) 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
EA200970535A1 (ru) Антибактериальные производные хинолина
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
TW200420549A (en) Thiazole derivatives
TNSN08408A1 (fr) PYRIDINE [3,4-b] PYRAZINONES
WO2006067165A3 (en) Indolidone derivatives for the treatment or prevention of fibrotic diseases
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EA200501820A1 (ru) Терапевтические средства для лечения боли
HUP0302336A2 (hu) 5-Klór-3-(4-metánszulfonilfenil)-6'-metil-[2,3']bipiridinil tiszta formában és eljárás előállítására
WO2008010238A3 (en) Antidiabetic azabicyclo [3. 1. 0] hexan compounds
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
RU2011112684A (ru) АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α
UA101305C2 (ru) Антибактериальные производные хинолина
SI1791537T1 (sl) 3-ariltioindol-2-karboksamidni derivati in njihovi analogi kot inhibitorji kazein-kinaze I
HK1137431A1 (en) Antibacterial quinoline derivatives
IL160082A0 (en) Quinoline derivatives and use thereof as antitumor agents
RU2008144660A (ru) Лизобактинамиды
TW200505869A (en) Thiophenylaminoimidazolines
EA200970536A1 (ru) Антибактериальные хинолиновые производные
JO2685B1 (en) Quinoline antibacterial derivatives
BRPI0416366A (pt) composto, composições correspondentes, métodos de preparação e/ou de tratamento
UA101307C2 (ru) Антибактериальные производные хинолина